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Metabolism of 25-[3H]hydroxyvitamin D3 was studied in peritoneal macrophages from renal failure patients 
on continuous ambulatory peritoneal dialysis (CAPD). Cells from 5 out of 8 patients with a history of peri- 
tonitis produced significant amounts of a metabolite chromatographically identical to I~,25(OH)2D3; but 
none was produced by cells from non-infected patients. The evidence strongly suggests that peritoneal mac- 
rophages stimulated by infection can metabolise 25OHD3 to the active vitamin D3 metabolite, 
1 ~,25(OH)2D3, when maintained in short-term primary culture. 
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1. INTRODUCTION 
The hormonally active metabolite of vitamin D3, 
I ol,25-dihydroxyvitamin D3 [IoG25(OH)2D3], 
which promotes intestinal absorption of calcium, 
is normally synthesized exclusively in the kidney 
from its precursor 25-hydroxyvitamin D3 
(25OHD3) [1]. However, patients with sarcoidosis 
who are hypercalcaemic have elevated plasma 
levels of lo~,25(OH)zD3 [2] thought to result from 
extra-renal synthesis by activated macrophages 
(Me) [3]. Further studies on cultured cells have 
shown that normal M~ activated by y-interferon 
[4] or bacterial lipopolysaccharides [5] also 
develop the ability to synthesise lol,25(OH)zD3. 
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We have addressed the problem as to whether 
activated M~b in patients on continuous ambulato- 
ry peritoneal dialysis (CAPD) with a history of 
peritonitis resulting from bacterial infection may 
produce lcr,25(OH)2D3. Extra-renal synthesis 
could prove significant in these patients in whom 
renaI synthesis of the active metabolite is likely to 
be severely impaired [6]. 
2. MATERIALS AND METHODS 
2.1. Isolation o f  peritoneal M~ f rom CAPD fluids 
Overnight CAPD fluid drains were collected 
from 8 patients with a history of peritonitis and 6 
patients who had no history of infection. Cells, 
predominantly Me, and monocytes (MN) with 
some neutrophils and lymphocytes, were harvested 
by centrifugation i  50-ml aliquots [7] and resus- 
pended in 4 ml RPMI-1640 medium supplemented 
with 10°70 fetal calf serum (Flow). These were in- 
cubated in 20-ml glass vials for 2 h at 36°C in an 
atmosphere of 95°7o air/5% CO2. Adherent M¢~ 
and non-adherent cells were separated, resuspend- 
ed in 2 ml serum-free RPMI-1640 medium con- 
taining 2 mM glutamine, 50 U/ml  penicillin and 
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50/zg/ml streptomycin and examined for the abili- 
ty to metabolise [3H]25OHD3. In a separate xperi- 
ment adherent cells from patient no. 5 were 
maintained in culture for 7 days before incubation 
with [3H]25OHD3. The morphology of the 
harvested cells was examined by light microscopy 
in all patients and also following Giemsa and non- 
specific esterase staining of cytocentrifuge 
preparations for selected patients. 
2.2. Metabolism of 250HD3 and 
chromatography of lipid extracts 
Approx. 100 pg [3H]25OHD3 (105 dpm; 176 Ci/ 
mmol) in 20/A ethanol were added to 1-20 × 10 6 
adherent, non-adherent or mixed cells from each 
patient. Incubations were carried out at 37°C in an 
atmosphere of 95o-/0 air/5°/0 CO2 overnight (17 h) 
and were terminated by adding 3 ml acetonitrile. 
The acetonitrile xtracts of each sample underwent 
preliminary purification on silica Sep-pak car- 
tridges (Waters Associates) [8] followed by 
analysis on HPLC using a Zorbax-SIL column 
developed with n-hexane, propan-2-ol, methanol 
Table 1 
(110:6:4, v/v) at 1.5 ml/min. 30-s fractions were 
collected and counted for 3H radioactivity. 
25OHD3 and lot,25(OH)2D3 standards (kindly 
donated by Dr M. Uskokovic) were also chromato- 
graphed and their retention times determined by 
UV absorption at 265 nm. The quantity of the 
labelled metabolite chromatographing with the 
same retention time as standard lo~,25(OH)2D3 was 
expressed as pg/106 cells. The identify of this 
metabolite was confirmed in a pooled sample of 
cell extracts by rechromatography on the above 
HPLC system and then by straight-phase (Zorbax 
SIL) and reverse-phase (Zorbax ODS) HPLC with 
mobile phases of 2.5°/0 methanol in dichloro- 
methane (1 ml/min) and 15% water in methanol 
(2 ml/min), respectively. 
3. RESULTS AND DISCUSSION 
The formation of a vitamin D metabolite, which 
chromatographs on HPLC with authentic 
lcr,25(OH)zD3, is clearly demonstrated in cells 
isolated from CAPD fluid drains in 5 out of 8 
Metabolism of [26,27-3H]25-hydroxyvitamin D3 in peritoneal 
macrophages from patients with or without a history of peritonitis 
Patient 1,25(OH)2D3 formation 
(pg/106 cells) 
Adherent Non-adherent 
macrophages cells 
Days since 
last bout of 
peritonitis 
1 22.90 0 65 (6) 
2 11.36 o.1 10 (3) 
3 2.82 0 12 (1) 
4 2.62 0.07 85 
5 1.19 0.26 7 
6 0 0 28 (1) 
7 0 0 22 (2) 
8 0 0 206 
5 1 week in 9.52 0 7 
culture 
9 0 0 no history 
10 0 0 of 
11 0 0 peritonitis 
12 0 0 
13 0 0 
14 0 0 
The number of previous episodes of peritonitis is given in 
parentheses 
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CAPD patients with a history of peritonitis (table 
1). This metabolic activity was further demon- 
strated to occur only in glass-adherent cells which 
have typical Me morphology. By contrast, 
adherent cells from 6 CAPD patients with no 
history of peritonitis did not synthesise 1ce,25 
(OH)2D3. A product of [3H]25OHD3 metabolism 
less polar than lcr,25(OH)2D3, with HPLC reten- 
tion similar to that of (5Z)-19-nor-10-oxo-25OHD3 
[9], appeared to be produced by non-adherent 
250HD3 1,25(0~zD~ 
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Fig.1. Metabolism in vitro of [3H]25OHD3 by cells har- 
vested from the CAPD fluid of a peritonitis patient. (A) 
Mixed cells, (B) adherent cells with M~ morphology, (C) 
non-adherent cells, (D) cell-free incubation. Bars repre- 
sent the amount of tritiated material in 30-s fractions ob- 
tained by HPLC analysis of cell extracts on a 
Zorbax-SIL column developed at 1.5 ml/min with n- 
hexane, propan-2-ol, methanol (110:6:4). Arrows in- 
dicate retention times of standard 25OHD3 and 
loe,25(OH)2D3 determined by UV absorbance (265 nm). 
cells, but this may be formed by non-specific ox- 
idation of 25OHD3 as it was also formed under 
cell-free control incubations (fig.l). 
A pooled sample of the [3H] lce,25(OH)2D3-1ike 
material produced by the adherent M¢ co- 
chromatographed with the authentic metabolite in 
three different HPLC systems thus providing good 
evidence for its identity (fig.2). 
Previous studies on the metabolism of 
[3H]25OHD3 by M~ have used cells maintained in 
cell culture for 4-10 days [3-5]. However, the cell 
culture conditions may themselves alter the pheno- 
type of the cells and perhaps influence their ability 
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Fig.2. Rechromatography of pooled [3H]l,25(OH)2D3 
produced by peritoneal M~, following initial chroma- 
tography on HPLC system (A), from patients with a 
history of peritonitis on 3 HPLC systems. (A) Zorbax- 
SIL column eluted at 1.5 ml/min with n-hexane, 
propan-2-ol, methanol (110: 6 : 4), (B) Zorbax-SIL col- 
umn eluted at 1 ml/min with 2.5°70 methanol in di- 
chloromethane, (C) Zorbax-ODS reverse-phase column 
eluted at 2 ml/min with 15% water in methanol. Bars 
represent the amount of tritiated material in l-ml frac- 
tions and the arrows indicate retention times of standard 
25OHD3 and lo~,25(OH)2D3 determined by UV absor- 
bance (265 nm). 
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to metabolise [~H]25OHD3. We have examined 
cells immediately after isolation using only a 2 h 
period to select glass-adherent Me and have 
demonstrated clearly the ability of such cells from 
CAPD patients with a history of peritonitis to 
form Ice,25(OH)zD3. After 7 days in culture cells 
from patient no. 5 formed increased amounts of 
loe,25(OH)zD3 (table 1). 
The MO appear to retain the capacity to form 
Icr,25(OH)zD3 many days after an episode of peri- 
tonitis (table 1). This could be explained if there 
were a static peritoneal population of ageing ac- 
tivated M~b. This, however, is unlikely because 
107-108 MN and MO are lost daily in CAPD fluid 
drains. An alternative explanation is that low- 
grade infection, resulting from bacterial colonisa- 
tion of the intraperitoneal catheters [10] or se- 
questration of viable bacteria within MN and M~ 
[11], may persist within the peritoneal cavity in the 
absence of clinical peritonitis and may provide 
continuous stimulation of MO. Variations in the 
degree of bacterial colonisation or sequestration 
may in part explain why only some of the peritoni- 
tis patients had Mq~ that could form 
lce,25(OH)2D3. 
Renal failure patients have an impaired ability to 
synthesise lo~,25(OH)2D3 [6] which may be exag- 
gerated by the loss of protein-bound 25OHD3 in 
CAPD fluid; it is thus possible that extra-renal for- 
mation of this metabolite might be significant in 
maintaining calcium homeostasis in CAPD pa- 
tients. Reported values for plasma lot,25(OH)2D3 
in CAPD patients are higher (mean 32.1, range 
6-81 pg/ml) [12] than those reported by different 
authors for patients treated by haemodialysis 
(mean 17.7, range 0-35 pg/ml) [13]. The 
significance of extra-renal Ice,25(OH)zD3 synthesis 
may be even greater when its role in haematolym- 
phopoietic tissue is considered. In vitro, lc~,25 
(OH)2D3 has been shown to promote the differen- 
tiation of MN towards the Mq~ phenotype. It also 
enhances M¢ function in non-specific immune 
processes uch as phagocytosis and inhibits inter- 
leukin-2 production by activated lymphocytes [14]. 
Thus, within the micro-environment of the im- 
mune response, lce,25(OH)2D3 secreted by 'ac- 
tivated' peritoneal Me may influence the function 
of lol,25(OH)2D3-responsive cells. 
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